101. Novel embelin‐loaded transniosomes for topical delivery: comprehensive exploration of in vitro, ex vivo and dermatokinetic assessment for anti‐cancer activity.
- Author
-
Alshetaili, Abdullah S, Almohizea, Salman, Anwer, Md. Khalid, and Riadi, Yassine
- Subjects
- *
RHODAMINE B , *SKIN cancer , *VITAMIN C , *CYTOTOXINS , *CHEMICAL industry - Abstract
BACKGROUND RESULTS CONCLUSION This study systematically designed and optimised a transniosomal formulation containing embelin for skin cancer management. The transniosomes were developed using a rotary evaporation method and then optimised using a Box–Behnken design.The optimized embelin‐loaded transniosomes (Opt‐EMB‐TNs) exhibited a vesicle size of 149.01 nm, polydispersity index of 0.184, a zeta potential of −21.14 mV, an entrapment efficiency of 75.6 ± 0.65%, drug loading of 3.36 ± 0.03% and drug release of 80.88 ± 2.55%. The antioxidant potential of Opt‐EMB‐TNs was found to be 88.54% when compared to standard ascorbic acid. Dermatokinetic studies showed a greater drug deposition in targeted skin areas with Opt‐EMB‐TN gel compared to the embelin conventional gel (EMB‐CF gel). In addition, the penetration depth study of the skin sample revealed that the transniosomal gel containing rhodamine B dye exhibited higher penetration than that of the rhodamine B dye containing hydroalcoholic solution. The efficacy of Opt‐EMB‐TNs for skin cancer was confirmed by cytotoxicity assay against the B16F10 melanoma cell line.The study concluded that the Opt‐EMB‐TN gel formulation is a promising and effective topical treatment for skin cancer, demonstrating significant potential for further development and clinical application. © 2024 Society of Chemical Industry. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF